Open AccessThe Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO
Author(s) -
Young Zoon Kim,
Chae Yong Kim,
Do Hoon Lim
Publication year - 2022
Publication title -
brain tumor research and treatment
Language(s) - English
Resource type - Journals
eISSN - 2288-2413
pISSN - 2288-2405
DOI - 10.14791/btrt.2022.0001
Subject(s) - medicine , guideline , glioma , cancer , disease , adjuvant , oncology , medline , adjuvant therapy , intensive care medicine , pathology , cancer research , political science , law
Gliomas have been histologically diagnosed as the third most common primary tumor of the central nervous system (CNS) in a relatively small portion of Korea. Despite the rarity of gliomas, the disease entity is very dynamic due to its various molecular characteristics, compared with other CNS tumors. The practice of managing glioma patients is not globally established as a precise standard guideline because of the different socio-medical environments of individual countries. The Korean Society for Neuro-Oncology (KSNO) published guidelines for managing adult glioma in 2019, and the National Comprehensive Cancer Network and European Association of Neuro-Oncology published guidelines in September 2021 and March 2021, respectively. However, these guidelines have several different recommendations in practice, including tissue management, adjuvant treatment after surgical resection, and salvage treatment for recurrent/progressive gliomas. Currently, the KSNO guideline working group is preparing an updated version of the guideline for managing adult gliomas. In this review, common features have been verified and different points are analyzed. Consequently, this review is expected to be informative and helpful to provide high quality evidence and a strong recommendation level for the establishment of new KSNO guidelines for managing gliomas.